公开(公告)号：US20230414560A1

公开(公告)日：2023-12-28

申请号：US18323032

申请日：2023-05-24

Applicant: General Nutraceutical Technology LLC

Inventor： Xiu-Min Li ,  Nan Yang ,  Zhenzhen Wang

IPC: A61K31/353 ,  A61P17/00 ,  A61K31/231 ,  A61K31/232 ,  A61K31/015 ,  A61K31/575 ,  A61K31/122 ,  A61K31/19 ,  A61K31/215 ,  A61K31/365 ,  A61K31/366 ,  A61K31/12 ,  A61K31/7048 ,  A61K31/404 ,  A61K9/06 ,  A61K36/076 ,  A61K36/65 ,  A61K36/21 ,  A61K36/355 ,  A61K36/30 ,  A61K36/634 ,  A61K36/48 ,  A61K36/484 ,  A61K36/185 ,  A61K36/232 ,  A61K36/489

CPC classification number: A61K31/353 ,  A61P17/00 ,  A61K31/231 ,  A61K31/232 ,  A61K31/015 ,  A61K31/575 ,  A61K31/122 ,  A61K31/19 ,  A61K31/215 ,  A61K31/365 ,  A61K31/366 ,  A61K31/12 ,  A61K31/7048 ,  A61K31/404 ,  A61K9/06 ,  A61K36/076 ,  A61K36/65 ,  A61K36/21 ,  A61K36/355 ,  A61K36/30 ,  A61K36/634 ,  A61K36/48 ,  A61K36/484 ,  A61K36/185 ,  A61K36/232 ,  A61K36/489

Abstract: A pharmaceutical composition for the treatment of eczema is disclosed. Also disclosed are methods of treating eczema in a subject by administering a pharmaceutical composition.

公开(公告)号：US20170319451A1

公开(公告)日：2017-11-09

申请号：US15590390

申请日：2017-05-09

Applicant: ELC Management LLC

Inventor： Nadine Pernodet ,  Donald F. Collins ,  Fatemeh Mohammadi

IPC: A61K8/365 ,  G01N33/50 ,  A61K8/06 ,  A61Q3/00 ,  A61K8/99 ,  A61K8/368 ,  A61Q5/00 ,  A61Q19/00

CPC classification number: A61K8/365 ,  A61K8/06 ,  A61K8/062 ,  A61K8/368 ,  A61K8/99 ,  A61K9/0014 ,  A61K31/618 ,  A61K35/745 ,  A61K35/747 ,  A61K36/076 ,  A61K36/31 ,  A61K36/38 ,  A61K36/45 ,  A61K36/47 ,  A61K36/535 ,  A61K36/82 ,  A61K47/14 ,  A61K2035/115 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q19/00 ,  G01N33/5038 ,  G01N33/5044 ,  G01N2800/7095 ,  A61K2300/00

Abstract: Compositions and methods for treating inflamed skin with Pro-Resolution Pathway Stimulators that may be Inflammatory Metabolite Inhibitors, Pro-Resolving Activators, or combinations thereof, and a method for screening active ingredients for activity as Pro-Resolution Pathway Stimulators for incorporation into topical cosmetic products.

公开(公告)号：US20170224746A1

公开(公告)日：2017-08-10

申请号：US15731100

申请日：2017-04-18

Applicant: John Edgar Menear ,  Joseph Ramaekers

Inventor： John Edgar Menear ,  Joseph Ramaekers

IPC: A61K35/744 ,  A23L33/135 ,  A61K41/00 ,  A23L33/00

CPC classification number: A61K35/744 ,  A23K10/16 ,  A23K20/158 ,  A23K20/163 ,  A23K20/168 ,  A23K40/30 ,  A23K40/35 ,  A23K50/10 ,  A23K50/60 ,  A23L33/135 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/145 ,  A61K31/7008 ,  A61K31/716 ,  A61K35/747 ,  A61K36/068 ,  A61K36/07 ,  A61K36/074 ,  A61K36/076 ,  A61K36/48 ,  A61K38/02 ,  A61K38/1703 ,  A61K41/0004 ,  A61K45/06 ,  A61K2035/11 ,  A61K2300/00

Abstract: A method of improving the outcome or recovery for depression, diabetes, cardiovascular disease, Alzheimers progression, or breast cancer. This method consists of administering a food which includes transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations and dosage levels. The food reduces cortisol levels, enhances the immune system, and balances hormones and cytokines. Dosage amounts are dependent on client weight. Consumption frequency and dosage may be adjusted. Typically, consumption of the food is done in combination with established medical treatments.

公开(公告)号：US09549957B2

公开(公告)日：2017-01-24

申请号：US13358369

申请日：2012-01-25

Applicant: Sabrina John

Inventor： Sabrina John

IPC: A61K36/076 ,  A61K36/899 ,  A61K9/00

CPC classification number: A61K36/076 ,  A61K9/0014 ,  A61K36/899 ,  A61K2300/00

Abstract: The present invention relates to an active agent complex of extracts of Poria cocos and a species of the genus Phragmites, in particular Phragmites kharka (also Phragmites karka), formulations comprising said active agent complex as well as to the use of the formulations of the invention for the strengthening, maintenance and quicker restoration of epidermal integrity.

Abstract translation: 本发明涉及茯苓提取物和芦苇属物种，特别是芦苇属（也是芦苇属）的活性剂复合物，其包含所述活性剂复合物的制剂以及本发明制剂的用途 用于加强，维持和更快恢复表皮完整性。

公开(公告)号：US09446086B2

公开(公告)日：2016-09-20

申请号：US13305453

申请日：2011-11-28

Applicant: Isaac Cohen

Inventor： Isaac Cohen

IPC: A61K36/00 ,  A61K36/185 ,  A61K36/48 ,  A61K36/481 ,  A61K36/484 ,  A61K36/58 ,  A61K36/488 ,  A61K36/076 ,  A61K36/21 ,  A61K36/284 ,  A61K36/296 ,  A61K36/40 ,  A61K36/489 ,  A61K36/539 ,  A61K36/62 ,  A61K36/638 ,  A61K36/65 ,  A61K36/708 ,  A61K36/725 ,  A61K36/884 ,  A61K36/8964 ,  A61K36/8965 ,  A61K36/899

CPC classification number: A61K36/488 ,  A61K36/076 ,  A61K36/21 ,  A61K36/284 ,  A61K36/296 ,  A61K36/40 ,  A61K36/48 ,  A61K36/481 ,  A61K36/484 ,  A61K36/489 ,  A61K36/539 ,  A61K36/62 ,  A61K36/638 ,  A61K36/65 ,  A61K36/708 ,  A61K36/725 ,  A61K36/884 ,  A61K36/8964 ,  A61K36/8965 ,  A61K36/899 ,  Y10S514/899 ,  A61K2300/00

Abstract: A novel herbal extract, MF101, is effective in the treatment of symptoms of menopause.

Abstract translation: 一种新颖的草药提取物MF101可有效治疗更年期症状。

公开(公告)号：US20160235802A1

公开(公告)日：2016-08-18

申请号：US14903277

申请日：2013-08-29

Applicant: Kuan-chih CHOW

Inventor： Kuan-Chih Chow

IPC: A61K36/69 ,  A61K9/16 ,  A61K36/258 ,  A61K36/076 ,  A61K36/481 ,  A61K36/484 ,  A61K36/725 ,  A61K36/185 ,  A61K36/232 ,  A61K36/9068 ,  A61K36/906 ,  A61K9/00 ,  A61K36/284

CPC classification number: A61K36/69 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/16 ,  A61K36/076 ,  A61K36/185 ,  A61K36/232 ,  A61K36/258 ,  A61K36/284 ,  A61K36/285 ,  A61K36/481 ,  A61K36/484 ,  A61K36/725 ,  A61K36/77 ,  A61K36/906 ,  A61K36/9068 ,  A61K2236/33 ,  A61K2236/331 ,  A61K2236/37 ,  A61K2236/53 ,  A61K2300/00

Abstract: A Chinese medicine capable of triggering lung adenocarcinoma cell autophagy mainly uses a polygala tenuifolia willd herb with a quantity depending on a patient's physical fitness and sickness conditions determined by a doctor, and capable of triggering a lung adenocarcionma cell autophagy (cracking) to achieve a treatment effect. Regardless of being taken as a powder or an extract, the medicine is capable of triggering the adenocarcionma cell autophagy (cracking) effect to achieve the treatment effect. The polygala tenuifolia willd applies a new protein transport mode as a target enzyme screening to successfully prove the effect of triggering lung adenocarcionma cell autophagy (cracking) for cancer treatment.

Abstract translation: 能够引发肺腺癌细胞自噬的中药主要使用一种根据医生确定的患者身体健康状况和疾病状况的多药耐药草药，并能够引发肺腺癌细胞自噬（破裂）以达到治疗 影响。 无论将其作为粉末或提取物，药物都能够引发腺癌细胞自噬（裂解）效应，达到治疗效果。 Polygala tenuifolia willd应用新的蛋白质转运模式作为靶酶筛选，以成功证明触发肺腺癌细胞自噬（裂解）对癌症治疗的作用。

公开(公告)号：US20150374778A1

公开(公告)日：2015-12-31

申请号：US14846786

申请日：2015-09-06

Applicant: Mingchun Xiao

Inventor： Mingchun Xiao

IPC: A61K36/9068 ,  A61K36/8988 ,  A61K36/07 ,  A61K36/752 ,  A61K36/284 ,  A61K36/484 ,  A61K36/575 ,  A61K36/236 ,  A61K36/232 ,  A61K36/237 ,  A61K36/268 ,  A61K36/85 ,  A61K36/185 ,  A61K36/46 ,  A61K36/21 ,  A61K36/515 ,  A61K36/54 ,  A61K36/258 ,  A61K36/65 ,  A61K36/804 ,  A61K36/481 ,  A61K36/714 ,  A61K36/12 ,  A61K36/884 ,  A61K36/8945 ,  A61K36/882 ,  A61K36/9062 ,  A61K36/734 ,  A61K36/8888

CPC classification number: A61K36/9068 ,  A23F3/163 ,  A61K36/07 ,  A61K36/076 ,  A61K36/12 ,  A61K36/185 ,  A61K36/21 ,  A61K36/232 ,  A61K36/233 ,  A61K36/236 ,  A61K36/237 ,  A61K36/258 ,  A61K36/268 ,  A61K36/284 ,  A61K36/46 ,  A61K36/48 ,  A61K36/481 ,  A61K36/482 ,  A61K36/484 ,  A61K36/515 ,  A61K36/53 ,  A61K36/532 ,  A61K36/535 ,  A61K36/538 ,  A61K36/539 ,  A61K36/54 ,  A61K36/575 ,  A61K36/65 ,  A61K36/66 ,  A61K36/68 ,  A61K36/71 ,  A61K36/714 ,  A61K36/734 ,  A61K36/752 ,  A61K36/804 ,  A61K36/85 ,  A61K36/88 ,  A61K36/882 ,  A61K36/884 ,  A61K36/888 ,  A61K36/8884 ,  A61K36/8888 ,  A61K36/8905 ,  A61K36/8945 ,  A61K36/8988 ,  A61K36/8998 ,  A61K36/906 ,  A61K36/9062 ,  A61K36/9064 ,  A61K36/9066 ,  A61K2300/00

Abstract: A pharmaceutical composition for treating cancers and preparation method thereof. Said composition for treating cancers contains Chinese medicinal materials including Rhizoma Pinelliae, Rhizoma Arisaematis, Rhizoma Gastrodiae etc., and said preparation method is in accordance with a conventional Chinese medicinal preparation method, manufacturing said composition to form any one of the ordinary oral preparations.

Abstract translation: 一种治疗癌症的药物组合物及其制备方法。 所述治疗癌症的组合物含有中药材，包括苦参，苦参，天麻等，所述制备方法按照常规的中药制备方法，制备所述组合物以形成任何一种普通口服制剂。

公开(公告)号：US20150093457A1

公开(公告)日：2015-04-02

申请号：US14043021

申请日：2013-10-01

Applicant: Jing Cheng ,  Chia-Wen Chen ,  Steven Francis Schnittger ,  Ming Lu

Inventor： Jing Cheng ,  Chia-Wen Chen ,  Steven Francis Schnittger ,  Ming Lu

IPC: A61K36/8998 ,  A61K36/41 ,  A61K36/185 ,  A61K36/756 ,  A61K36/235 ,  A61K36/752 ,  A61K36/535

CPC classification number: A61K36/725 ,  A61K8/97 ,  A61K8/99 ,  A61K36/06 ,  A61K36/068 ,  A61K36/074 ,  A61K36/076 ,  A61K36/10 ,  A61K36/16 ,  A61K36/185 ,  A61K36/23 ,  A61K36/235 ,  A61K36/236 ,  A61K36/258 ,  A61K36/28 ,  A61K36/41 ,  A61K36/535 ,  A61K36/539 ,  A61K36/65 ,  A61K36/69 ,  A61K36/704 ,  A61K36/752 ,  A61K36/756 ,  A61K36/804 ,  A61K36/8998 ,  A61K2800/85 ,  A61Q19/00

Abstract: The present invention relates to topical compositions containing fermented extracts of Traditional Chinese Medicinal (TCM) ingredients for improving the appearance and skin condition of the user. The topical compositions of the present invention are tailored for different users of different skin compositions according to TCM principles. The fermented TCM extracts are characterized by reduced odor and/or color in comparison with unfermented TCM extracts and are therefore more suitable for use in cosmetic products.

公开(公告)号：US20150079128A1

公开(公告)日：2015-03-19

申请号：US14029963

申请日：2013-09-18

Applicant: Hong Kong Baptist University

Inventor： Zhaoxiang Bian ,  Siu Wai Tsang ,  Siu Po Ip ,  Che Yuen Justin Wu ,  Aiping Lu ,  Albert Sun Chi Chan

IPC: A61K36/9068 ,  A61K36/718 ,  A61K36/076 ,  A61K36/71 ,  A61K36/344 ,  A61K36/284

CPC classification number: A61K36/9068 ,  A61K36/076 ,  A61K36/284 ,  A61K36/344 ,  A61K36/65 ,  A61K36/71 ,  A61K36/718 ,  A61K2300/00

Abstract: This invention relates to a Chinese medicinal formulation for the treatment of inflammatory bowel diseases, and a method of preparation thereof. The formulation comprises herbal components selected from a group consisting of Radix Codonopsis (Dangshen), Rhizoma Atractylodis Macrocephalae (Bai Zhu), Sclerotium Poriae Cocos (Fu Ling), Rhizoma Zingiberis Officinalis (Gan Jiang), Radix Paeoniae Alba (Bai Shao) and Rhizoma Coptidis (Huanglian).

Abstract translation: 本发明涉及一种治疗炎性肠病的中药制剂及其制备方法。 该制剂包含选自由党参（Dangshen），白术（白芍），茯苓（Fu Ling），an姜（Gan Jiang），白芍（Bai Shao），白芍（Rhizoma） 黄连（黄连）。

公开(公告)号：US20140234366A1

公开(公告)日：2014-08-21

申请号：US13822864

申请日：2013-02-21

Applicant: Yoshiteru Shimoide

Inventor： Yoshiteru Shimoide

IPC: A61K36/756 ,  A61K36/539 ,  A61K36/744 ,  A61K36/258 ,  A61K36/481 ,  A61K36/284 ,  A61K36/233 ,  A61K36/232 ,  A61K36/71 ,  A61K36/752 ,  A61K36/9068 ,  A61K36/725 ,  A61K36/484 ,  A61K36/076 ,  A61K36/54 ,  A61K36/718

CPC classification number: A61K36/756 ,  A61K36/00 ,  A61K36/076 ,  A61K36/232 ,  A61K36/233 ,  A61K36/258 ,  A61K36/284 ,  A61K36/481 ,  A61K36/484 ,  A61K36/539 ,  A61K36/54 ,  A61K36/71 ,  A61K36/718 ,  A61K36/725 ,  A61K36/744 ,  A61K36/752 ,  A61K36/9068 ,  A61K2300/00

Abstract: The invention aims to provide a composition for treating atopic dermatitis, bronchial asthma, allergic rhinitis or major depressive disorder (depression), comprising a mixture of Formula antidoti coptidis (orengedokuto) and Formula repletionis animalis et supletionis medii (hochuekkito) or a mixture of Formula antidoti coptidis (orengedokuto) and Formula glycyrrhizae atractylodis cinnamomi hoelen (ryokeijutsukanto) as active components. Provided is a composition for preventing or treating an allergic disease or major depressive disorder, comprising a mixture of Formula antidoti coptidis (orengedokuto) and Formula repletionis animalis et supletionis medii (hochuekkito) or a mixture of Formula antidoti coptidis (orengedokuto) and Formula glycyrrhizae atractylodis cinnamomi hoelen (ryokeijutsukanto) as active components.

Abstract translation: 本发明旨在提供一种用于治疗特应性皮炎，支气管哮喘，过敏性鼻炎或重度抑郁障碍（抑郁症）的组合物，其包含式antidoti coptidis（orengedokuto）和配方补充药物和药物组合物（hochuekkito）或式 antidoti coptidis（orengedokuto）和配方甘草（Atylylodis cinnamomi hoelen）（ryokeijutsukanto）作为活性成分。 提供了用于预防或治疗过敏性疾病或重症抑郁障碍的组合物，其包含式antidoti coptidis（orengedokuto）和Formula repletionis animalis et supletionis medii（hochuekkito）或式antidoti coptidis（orengedokuto）和Formula glycyrrhizae atractylodis的混合物的混合物 肉桂仁（ryokeijutsukanto）作为活性成分。